BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 17852899)

  • 1. Long-term use of daptomycin for MRSA osteomyelitis and joint infection.
    Burns CA
    Scand J Infect Dis; 2008; 40(2):183-6. PubMed ID: 17852899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin.
    Vikram HR; Havill NL; Koeth LM; Boyce JM
    J Clin Microbiol; 2005 Oct; 43(10):5384-7. PubMed ID: 16208025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis.
    Rouse MS; Piper KE; Jacobson M; Jacofsky DJ; Steckelberg JM; Patel R
    J Antimicrob Chemother; 2006 Feb; 57(2):301-5. PubMed ID: 16361330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection.
    Rouse MS; Steckelberg JM; Patel R
    Diagn Microbiol Infect Dis; 2007 Jul; 58(3):363-5. PubMed ID: 17449212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daptomycin for methicillin-resistant Staphylococcus aureus infections of the spine.
    Burdette SD
    Spine J; 2009 Jun; 9(6):e5-8. PubMed ID: 19112049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of daptomycin combined with rifampicin for the treatment of experimental meticillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis.
    Lefebvre M; Jacqueline C; Amador G; Le Mabecque V; Miegeville A; Potel G; Caillon J; Asseray N
    Int J Antimicrob Agents; 2010 Dec; 36(6):542-4. PubMed ID: 20851576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
    Marty FM; Yeh WW; Wennersten CB; Venkataraman L; Albano E; Alyea EP; Gold HS; Baden LR; Pillai SK
    J Clin Microbiol; 2006 Feb; 44(2):595-7. PubMed ID: 16455920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Problems with teicoplanin in the treatment of osteoarticular infections caused by methicillin-resistant S. aureus].
    Gómez J; Climent C; Herrero F; Ruano L
    Enferm Infecc Microbiol Clin; 1992 Nov; 10(9):567-8. PubMed ID: 1489810
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry.
    Martone WJ; Lamp KC
    Curr Med Res Opin; 2006 Dec; 22(12):2337-43. PubMed ID: 17257448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of daptomycin for Staphylococcus aureus infections in critical care medicine.
    Alder J
    Crit Care Clin; 2008 Apr; 24(2):349-63, ix-x. PubMed ID: 18361950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empiric antibiotic therapy for acute osteoarticular infections with suspected methicillin-resistant Staphylococcus aureus or Kingella.
    Saphyakhajon P; Joshi AY; Huskins WC; Henry NK; Boyce TG
    Pediatr Infect Dis J; 2008 Aug; 27(8):765-7. PubMed ID: 18600193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermediate vancomycin susceptibility in a community-associated MRSA clone.
    Graber CJ; Wong MK; Carleton HA; Perdreau-Remington F; Haller BL; Chambers HF
    Emerg Infect Dis; 2007 Mar; 13(3):491-3. PubMed ID: 17552110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia.
    Lalani T; Boucher HW; Cosgrove SE; Fowler VG; Kanafani ZA; Vigliani GA; Campion M; Abrutyn E; Levine DP; Price CS; Rehm SJ; Corey GR; Karchmer AW;
    J Antimicrob Chemother; 2008 Jan; 61(1):177-82. PubMed ID: 17999973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful oral pristinamycin therapy for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA) and other Staphylococcus spp.
    Ng J; Gosbell IB
    J Antimicrob Chemother; 2005 Jun; 55(6):1008-12. PubMed ID: 15845784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
    Huang YT; Hsiao CH; Liao CH; Lee CW; Hsueh PR
    J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin.
    Skiest DJ
    J Clin Microbiol; 2006 Feb; 44(2):655-6. PubMed ID: 16455939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.
    Mangili A; Bica I; Snydman DR; Hamer DH
    Clin Infect Dis; 2005 Apr; 40(7):1058-60. PubMed ID: 15825002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE) in a patient with Job's syndrome (hyperimmunoglobulin E syndrome) successfully treated with linezolid and high-dose daptomycin.
    Cunha BA; Krol V; Kodali V
    Heart Lung; 2008; 37(1):72-5. PubMed ID: 18206530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
    Bennett JW; Murray CK; Holmes RL; Patterson JE; Jorgensen JH
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):437-40. PubMed ID: 18096352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with daptomycin for the treatment of patients with osteomyelitis.
    Lamp KC; Friedrich LV; Mendez-Vigo L; Russo R
    Am J Med; 2007 Oct; 120(10 Suppl 1):S13-20. PubMed ID: 17904946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.